• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环游离 DNA 检测用于诊断肝细胞癌的准确性:系统评价和荟萃分析。

Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis.

机构信息

Department of Radiology, The First Hospital of Lanzhou University, Lanzhou City, Gansu Province, China.

Department of Intelligent Science and Technology, Intelligent Imaging Medical Engineering Research Center of Gansu Province, Guangzhou City, Guangdong Province, China.

出版信息

Expert Rev Mol Diagn. 2023 Jan;23(1):63-69. doi: 10.1080/14737159.2023.2167555. Epub 2023 Jan 18.

DOI:10.1080/14737159.2023.2167555
PMID:36633401
Abstract

INTRODUCTION

Circulating cell-free DNA (cfDNA) is a good diagnostic tool for hepatocellular carcinoma as it can comprehensively reflect the heterogeneity of tumors and aid in their early detection. This study aimed to assess the diagnostic value of circulating cfDNA for hepatocellular carcinoma.

METHODS

PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus databases were searched to identify all relevant literature from their dates of establishment to 6 April 2022, and a total of 2,467 articles were found. Methodological quality assessment was performed using QUADAS-2.

RESULTS

Fifteen articles with 3,686 patients were included in this study after screening. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.83 (95% confidence interval [CI]: 0.78, 0.87), 0.90 (95% CI: 0.86, 0.93), 8.4 (95% CI: 5.9, 12.0), 0.19 (95% CI: 0.15, 0.24), 44 (95% CI: 30, 66), and 0.93 (95% CI: 0.90, 0.95), respectively. Deek's funnel plot test did not show significant publication bias (P = 0.28).

CONCLUSIONS

Results of this meta-analysis suggest that circulating cfDNA has moderate sensitivity and excellent specificity for the detection of hepatocellular carcinoma as a noninvasive test (0.83 and 0.90, respectively).

摘要

简介

循环游离 DNA(cfDNA)是一种用于诊断肝细胞癌的良好工具,因为它可以全面反映肿瘤的异质性,并有助于早期发现。本研究旨在评估循环 cfDNA 对肝细胞癌的诊断价值。

方法

检索 PubMed、EMBASE、Web of Science、Cochrane Library 和 Scopus 数据库,从建库日期至 2022 年 4 月 6 日,共检索到 2467 篇相关文献。使用 QUADAS-2 进行方法学质量评估。

结果

经过筛选,本研究共纳入 15 篇文献,共计 3686 例患者。汇总后的敏感性、特异性、阳性似然比、阴性似然比、诊断优势比和曲线下面积分别为 0.83(95%置信区间[CI]:0.78,0.87)、0.90(95% CI:0.86,0.93)、8.4(95% CI:5.9,12.0)、0.19(95% CI:0.15,0.24)、44(95% CI:30,66)和 0.93(95% CI:0.90,0.95)。Deek 漏斗图检验未显示出显著的发表偏倚(P=0.28)。

结论

本荟萃分析结果表明,循环 cfDNA 作为一种非侵入性检测方法,对肝细胞癌的检测具有中等敏感性和极好的特异性(分别为 0.83 和 0.90)。

相似文献

1
Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis.循环游离 DNA 检测用于诊断肝细胞癌的准确性:系统评价和荟萃分析。
Expert Rev Mol Diagn. 2023 Jan;23(1):63-69. doi: 10.1080/14737159.2023.2167555. Epub 2023 Jan 18.
2
Diagnostic performance of circulating cell-free DNA for hepatocellular carcinoma: a systematic review and meta-analysis.循环游离 DNA 检测在肝细胞癌中的诊断性能:系统评价和荟萃分析。
Biomark Med. 2021 Feb;15(3):219-239. doi: 10.2217/bmm-2020-0334. Epub 2021 Jan 20.
3
Detection of Circulating Cell-free DNA to Diagnose Hepatocellular Carcinoma in Chinese Population: A Systematic Review and Meta-analysis.检测循环游离 DNA 诊断中国人肝细胞癌:系统评价和荟萃分析。
Curr Med Chem. 2024;31(22):3345-3359. doi: 10.2174/0929867330666230622114235.
4
Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis.长链非编码 RNA 作为肝细胞癌诊断标志物的研究:Meta 分析。
Pathol Res Pract. 2021 Aug;224:153546. doi: 10.1016/j.prp.2021.153546. Epub 2021 Jul 9.
5
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.循环游离 DNA 在卵巢癌中的诊断意义评估:一项更新的荟萃分析。
Gene. 2019 Sep 25;714:143993. doi: 10.1016/j.gene.2019.143993. Epub 2019 Jul 19.
6
Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma: An Updated Meta-Analysis.lncRNAs 作为肝癌生物标志物的诊断价值:一项更新的荟萃分析。
Can J Gastroenterol Hepatol. 2018 Oct 15;2018:8410195. doi: 10.1155/2018/8410195. eCollection 2018.
7
Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis.循环游离DNA定量和定性分析作为肝细胞癌诊断工具的价值:一项荟萃分析
Medicine (Baltimore). 2015 Apr;94(14):e722. doi: 10.1097/MD.0000000000000722.
8
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.循环游离DNA分析作为乳腺癌诊断工具的价值:一项荟萃分析
Oncotarget. 2017 Apr 18;8(16):26625-26636. doi: 10.18632/oncotarget.15775.
9
Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis.利用循环肿瘤 DNA 作为新型生物标志物筛查和诊断肝细胞癌:系统评价和荟萃分析。
Cancer Med. 2020 Feb;9(4):1349-1364. doi: 10.1002/cam4.2799. Epub 2019 Dec 26.
10
[Meta-analysis on the diagnostic value of laser Doppler imaging for burn depth].[激光多普勒成像对烧伤深度诊断价值的Meta分析]
Zhonghua Shao Shang Za Zhi. 2017 May 20;33(5):301-308. doi: 10.3760/cma.j.issn.1009-2587.2017.05.009.

引用本文的文献

1
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.肝细胞癌肝动脉灌注化疗的预测因素及预后模型:一项综述
World J Surg Oncol. 2025 Apr 26;23(1):166. doi: 10.1186/s12957-025-03765-7.
2
Persisting challenges in the early detection of hepatocellular carcinoma.肝细胞癌早期检测中持续存在的挑战。
Expert Rev Anticancer Ther. 2025 Feb 24:1-12. doi: 10.1080/14737140.2025.2467184.
3
Potentialities and critical issues of liquid biopsy in clinical practice: An umbrella review.
液体活检在临床实践中的潜力与关键问题:一项综合综述。
Transl Oncol. 2025 Feb;52:102172. doi: 10.1016/j.tranon.2024.102172. Epub 2025 Jan 15.
4
Non-Invasive Biomarkers and Breath Tests for Diagnosis and Monitoring of Chronic Liver Diseases.用于慢性肝病诊断和监测的非侵入性生物标志物及呼气试验
Diagnostics (Basel). 2024 Dec 30;15(1):68. doi: 10.3390/diagnostics15010068.
5
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.用于肝细胞癌诊断和治疗选择的生物标志物。
Mol Cancer. 2024 Sep 6;23(1):189. doi: 10.1186/s12943-024-02101-z.
6
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.肝细胞癌的分子和免疫格局以指导治疗决策。
Hepatology. 2025 Mar 1;81(3):1038-1057. doi: 10.1097/HEP.0000000000000513. Epub 2023 Jun 12.